PharmTech’s Weekly Roundup—September 25, 2026

This week, new modalities keep raising the manufacturing bar even as regulators race to modernize the rules around them, and artificial intelligence (AI) is showing up in validated environments as both a promised efficiency and a complication for quality teams. From weekly insulin to oral oncology combos to a new EU-cleared triple-therapy inhaler, the chemistry, manufacturing, and controls (CMC) complexity keeps climbing, right alongside the debate over how much oversight AI-assisted work needs.

In the News….

In news this week, the FDA issued its direct final rule swapping "animal studies" for "nonclinical studies" throughout its regulations, which gives sponsors clearer footing to submit data from organ-on-chip and other new approach methodologies in investigational new drug (IND) and marketing applications.

The FDA approved Lilly’s once-weekly insulin efsitora alfa-gobe, branded Onswik, which is a treatment that can cut patients’ basal insulin injections from 365 a year to just 52 while setting a new high-concentration formulation benchmark for biologics CMC teams.

The FDA also approved Lilly's Inluriyo paired with Verzenio for ESR1-mutated breast cancer, which more than doubled progression-free survival to 11.1 months, but the 2-pill oral regimen also leans hard on ESR1 diagnostic testing and coordinated supply planning across separately manufactured products.

AstraZeneca’s clearance in the European Union of Trixeo Aerosphere for asthma extends single-inhaler triple therapy beyond chronic obstructive pulmonary disease (COPD), adding pressure on canister, valve, and actuator suppliers just as respiratory manufacturers race to requalify formulations for near-zero-global warming potential (GWP) propellants.

Autumn Conference Previews

In conference news, CPHI Milan’s return of its invitation-only Leadership Summit puts supply-chain resilience front and center, with event director Tara Dougal noting that manufacturers are making strategic sourcing and location decisions against what she called an “evolving backdrop” of geopolitical fragmentation.

Featured Content

PharmTech launched its new AI Pulse Check video series. In the first episode, OpenBiopharma’s Richard Jaenisch flagged deviation reports as generative AI’s easiest entry point into manufacturing documentation, warning that the speed gained from automating form-filling can come at the expense of the judgment those reports are supposed to capture.

In another episode, independent regulatory advisor Florin Muraru argued multi-agent AI systems can be allowed to communicate freely on the plant floor as long as humans sign off on every GxP-critical action before it executes.

In the latest Ask the Expert episode, Parexel’s Siegfried Schmitt and Nelson Labs’ Susan Schniepp walked through how to plan for post-approval CMC changes, reminding manufacturers that production is never static and that choosing the right regulatory pathway starts with anticipating what's coming before the original filing goes in.

In Pharma Fundamentals, Charles River’s Aleksandra Zuraw explained why digital pathology is becoming a validated, Part 11-compliant data system rather than a lab convenience, with traceable tissue data now spanning everything from early toxicology to post-market diagnostics.

And finally, Cheryl Barton’s look at Sweden's biotech sector found early-stage innovation across CNS, cell and gene therapy, and rare disease accelerating since mid-2025, fueled by out-licensing deals and strategic tie-ups with the likes of Lilly and Roche.

Taken together, this week’s stories show that new modalities and combinations are pushing CMC complexity higher, regulators are modernizing decades-old rules, and AI is arriving in validated workflows as both a promised efficiency and a fresh risk to manage.